Natixis Avidity Biosciences, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
A detailed history of Natixis transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Natixis holds 1,675 shares of RNA stock, worth $52,997. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,675
Previous 1,765
5.1%
Holding current value
$52,997
Previous $72,000
5.56%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding RNA
# of Institutions
255Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$336 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$292 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$273 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$257 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$222 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.65B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...